In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA ...
Disc Medicine's strong financial position, with $489.9 million in cash and securities, ensures funding through 2028, reducing near-term financing risks. Lead asset Bitopertin shows promise in treating ...
The last time I spoke about Disc Medicine (IRON) was in a Seeking Alpha article known as "Disc Medicine: Rare Disease Biotech With Enormous Potential." In the article, I laid out that IRON had already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results